Panel rejects Sanofi’s waiver plea for dengue vaccine
French drug and vaccines giant Sanofi suffered a setback in introducing its much-awaited dengue vaccine Dengvaxia in India after a top health ministry committee rejected its request to waive additional clinical studies.
The decision of the apex committee is expected to delay the entry of the vaccine, which has been approved in Mexico, the Philippines and Brazil to combat the mosquito-borne disease.
The race to beat dengue is picking up momentum, though. Sun Pharmaceuticals, India’s largest drug maker, announced on Wednesday a partnership with nonprofit research organisation International Centre for Genetic Engineering and Biotechnology to develop a botanical drug to fight the dengue virus.
- Health Care